Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained

Merav A. Ben David 1,2,†, Ella Evron 3,4,*†©, Adi F. Rasco 5, Ayelet Shai 6,7 and Benjamin W. Corn 4,8

1 Assuta Medical Center, Tel Aviv 6971028, Israel; meravak@assuta.co.il
2 Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel
3 Oncology, Kaplan Medical Institution, Rehovot 7661041, Israel
4 Faculty of Medicine, The Hebrew University, Jerusalem 91120, Israel; Ben.w.corn@gmail.com or bencorn@szmc.org.il
5 Shamir Medical Center and Sackler School of Medicine, Tel-Aviv University, Tel Aviv 7033001, Israel; rascoa@shamir.gov.il
6 Department of Oncology, Galilee Medical Center, Naharia 22100, Israel; AyeletS@gmc.gov.il
7 Azrieli Faculty of Medicine, Bar Ilan University, Ramat Gan 5290002, Israel
8 Shaare Zedek Medical Center, Jerusalem 9103102, Israel
* Correspondence: evronel@gmail.com or allaev@clalit.org.il
† These authors have equal contribution to this work.

Simple Summary: In this study we report the outcome of salvage mastectomy and reconstruction in 11 BRCA mutation carrier patients that participated in a clinical trial of prophylactic contralateral breast irradiation and suffered recurrences of breast cancer in either the ipsilateral or contralateral breast or elected to have the procedure for risk reduction. Patients' satisfaction and physicians' assessment of the cosmetic outcome were not inferior for previously irradiated compared to non-irradiated breasts. These results are encouraging and support continuing research as well as a discussion of risk-reduction alternatives besides mastectomy, including prophylactic breast irradiation, in BRCA1/2 mutation carriers.

Abstract: Risk-reducing mastectomy (RRM) is often advocated for BRCA1/2 mutation carriers who face a heightened lifetime risk of breast cancer. However, many carrier patients seek alternative risk-reducing measures. In a phase II nonrandomized trial, we previously reported that prophylactic irradiation to the contralateral breast among BRCA carriers undergoing breast-conserving treatment significantly reduced subsequent contralateral breast cancer. Herein, we report the outcome of salvage mastectomy and reconstruction in 11 patients that suffered recurrences of breast cancer in either the ipsilateral or contralateral breast or elected to have the procedure for risk reduction during the eight-year follow-up period. Patients' satisfaction with the procedure and physicians' assessment of the cosmetic outcome were not inferior for previously irradiated compared to non-irradiated breasts. Although the numbers are small, the results are encouraging and sustain hope in a challenging population. Our findings support continuing research as well as a discussion of risk-reduction alternatives besides mastectomy, including prophylactic breast irradiation, in BRCA1/2 mutation carriers.

Keywords: breast cancer; BRCA mutation; prophylactic breast irradiation

1. Introduction

BRCA mutations are particularly prevalent in Israel, as 2.5% of the Ashkenazi Jewish population, which comprises about 50% of Jewish Israelis, carry a specific founder mutation in BRCA1 or BRCA2. Accordingly, 20% of young-age (<40) breast cancers that arise in Israeli women are attributed to these mutations [1,2]. The management of BRCA-associated breast cancer, therefore, presents recurring challenges for Israeli oncologists. Women with
BRCA-associated breast cancer often present at a relatively young age with decidedly more aggressive cancers [3]. Moreover, they face a high risk of developing contralateral breast cancer as well as ovarian cancer [4]. Consequently, mastectomy of the diseased breast as well as risk-reducing mastectomy (RRM) of the contralateral breast are, by necessity, part of the treatment discussion with these patients. Notwithstanding, the decision to remove one’s breasts is not easy, and behooves intimate discourse between a woman, her body, and her “womanhood”. Therefore, additional risk-reducing measures are needed for BRCA mutation carriers who forgo mastectomy.

Between 2007 and 2017, 162 BRCA mutation carriers with unilateral breast cancer were enrolled in a national phase II nonrandomized trial, where the patients had the option of prophylactic contralateral breast irradiation (Figure S1). At a median follow up of five years, 10 patients developed contralateral breast cancer in the control arm as compared with two patients in the intervention arm (log-rank \( P = 0.011 \)) [5]. The addition of contralateral breast irradiation was associated with a significant reduction of subsequent contralateral breast cancers and a delay in their onset. Longer follow up is needed and continues [6]; nevertheless, some investigators have posited that the data already justify offering bilateral irradiation to BRCA carriers undergoing treatment for breast cancer [7]. To the best of our knowledge, no other studies are investigating contralateral prophylactic radiotherapy in hereditary breast cancer patients (clinicaltrials.gov, accessed 14 May 2020). During the follow-up period, a minority of the patients experienced subsequent ipsilateral or contralateral breast cancer necessitating salvage procedures, and few patients elected to pursue risk-reducing mastectomy plus reconstruction.

It has been suggested that prior breast irradiation may increase complications and jeopardize cosmesis of subsequent breast reconstruction [8]. The optimal timing and technique of breast reconstruction in patients who need chest-wall irradiation (PMRT) is controversial [8,9], and it has been repeatedly reported that chest wall irradiation is associated with inferior reconstructive results. Thus, in patients undergoing implant-based reconstruction, PMRT increases rates of infections, capsular contracture, implant loss and overall reconstructive failure requiring revision surgeries, whereas in patients undergoing autologous reconstruction, PMRT has been associated with fibrosis, distortion of breast shape, volume loss, and fat necrosis. Moreover, patient-reported outcomes after reconstruction are lower in women receiving PMRT [8]. Therefore, we elected to carefully review and report the outcome of breast reconstruction among trial participants that underwent bilateral mastectomy and reconstruction during the follow-up period.

2. Methods

Permission to proceed with the aforementioned analysis was obtained from the Institutional Review Board (IRB) at Kaplan Medical Center (Rehovot, Israel). We systematically contacted the trial participants that had mastectomy and reconstruction during the follow-up period and requested their consent for participation in this secondary analysis. Patients who were willing to participate were invited to return to the clinic for an evaluation visit that included photo-documentation. We asked patients who were not willing to come, especially in view of the COVID-19 pandemic, to consent to an interview by phone and to submit their own photos. We used the Baker score—a validated four-point rating scale ranging from excellent to poor cosmetic result—for evaluation of the reconstruction on both sides [10]. We instructed the patients to score their satisfaction from 1 to 10, where 10 is maximal satisfaction. The treating physicians scored their impression using the Baker score, based on their physical examination (when performed) or based on the pictures that were submitted by the patients. In most cases, multiple photos, including anterior and lateral pictures, were provided. We then selected the most representative photographs for display in Tables 1 and 2, respectively. The choice of plastic surgeon and type of reconstruction surgery were determined by the patient and her physician, respectively. All the photos and satisfaction scores were obtained recently in preparation for this report.
### Table 1. Mastectomy and reconstruction after prophylactic breast irradiation.

| #  | Year of Birth | Irradiation Therapy (AGE) | Reconstruction Reason, Type | Satisfaction Patients 1-10 | Baker Score | Photo |
|----|---------------|---------------------------|----------------------------|-----------------------------|-------------|-------|
| 1B | 1972          | Bilateral 2013 (41)       | RT-10/10                   | Lt-7/10                     | Rear-1       |       |
| 2B | 1964          | Bilateral 2015 (51)       | RT-10/10                   | Lt-10/10                    | Rear-1       |       |
| 3B | 1947          | Bilateral 2010 (63)       | RT-7/10                    | Lt-7/10                     | Rear-2       |       |
| 4B *| 1972         | Bilateral 2010 (38)       | RT-4/10                    | Lt-3/10                     | Rear-4       |       |

* This patient was a heavy smoker and has severe scoliosis. CLT—contralateral; DCIS—ductal carcinoma in situ; Ca—cancer; Local Rec.—local recurrence; SSM—skin-sparing mastectomy; NSSM—nipple- and skin-sparing mastectomy.
### Table 2. Mastectomy and reconstruction of non-irradiated breasts.

| #  | Year of Birth | Irradiation Therapy (AGE) | Reconstruction Reason, Type | Satisfaction Patients 1-10 | Baker Score | Photos |
|----|---------------|---------------------------|-----------------------------|----------------------------|-------------|--------|
| 1C | 1966         | Lt. breast 2010 (44)     | 2012 Risk Reduc. SSM Silicon | Rt-8/10 Lt-8/10            | Rt-1 Lt-1  | ![Image](.../cancer_bilateral_2010.jpg) |
| 2C | 1965         | Lt. breast 2010 (45)     | 2015 Local Rec. SSM Silicon | Rt-7/10 Lt-9/10            | Rt-4 Lt-2  | ![Image](.../cancer_local_2015.jpg) |
| 3C | 1965         | Rt. Breast 2011 (46)     | 2012 Risk Reduc. SSM Silicon | Rt-8/10 Lt-8/10            | Rt-2 Lt-1  | ![Image](.../cancer_risk_2012.jpg) |
| 4C | 1970         | Lt. breast 2011 (41)     | Lt- 2011 NSSSM Silicon Bil. 2017 tear of implant | Rt-3/10 Lt-6/10            | Rt-3 Lt-2  | ![Image](.../cancer NSSSM_2011.jpg) |
Risk Reduc.—risk reduction; CLT—contralateral; DCIS—ductal carcinoma in situ; Ca—cancer; Local Rec.—local recurrence; SSM—skin-sparing mastectomy; NSSM—nipple- and skin-sparing mastectomy.

Table 2. Cont.

| #  | Year of Birth | Irradiation Therapy (AGE) | Reconstruction Reason, Type | Satisfaction Patients 1-10 | Baker Score | Photos |
|----|---------------|----------------------------|-----------------------------|-----------------------------|-------------|--------|
| 5C | 1974          | Lt. breast 2014 (40)      | 2015 Risk Reduc. SSM Silicon | Rt-10/10 Lt-10/10           | Rt-1        | Lt-2   |
| 6C | 1973          | Rt. Breast 2016 (43)      | 2018 CLT Ca. SSM Silicon    | Rt-5/10 Lt-6/10             | Rt-4        | Lt-3   |
| 7C | 1978          | Lt. Breast 2017 (39)      | 2019 Risk Reduc. NSSM Silicon | Rt-9/10 Lt-9/10           | Rt-2        | Lt-2   |

Pt. declined to have her picture published
3. Results

Five patients in the experimental arm who received contralateral risk-reducing irradiation underwent subsequent bilateral mastectomy and reconstruction, three following contralateral breast cancer (pt. 1B, 2B, 4B), one after ipsilateral cancer recurrence (pt. 3B), and one for risk reduction without contralateral disease, as seen in Table 1. The latter patient declined to participate in this report or to submit pictures. The median time between bilateral irradiation and surgery was 5.5 years (range five to seven years).

Twelve patients in the control group who received standard treatment to the ipsilateral breast only underwent subsequent mastectomy and reconstruction of the contralateral breast, three following contralateral breast cancer (pt. 4C, 6C, and one patient that did not wish to participate or send pictures), one patient after ipsilateral cancer recurrence (pt. 2C), and eight patients for risk reduction without disease (pt. 1C, 3C, 5C, 7C, and four patients that did not wish to participate or send pictures), as seen in Table 2. The median time between ipsilateral breast irradiation and surgery was two years (range one to five years).

The average Baker score was 2.14 both for reconstruction after breast irradiation (14 breasts) and for reconstruction without previous breast irradiation (seven breasts). Most patients in both groups were pleased with their reconstruction outcome (average 7.64/10 for reconstruction after prior prophylactic irradiation and 7.29/10 for reconstruction without prior breast irradiation)—see Table 3—implying that prior breast irradiation did not compromise subsequent reconstruction results. One patient in the experimental arm (prior prophylactic irradiation) and five in the control arm who had mastectomy and reconstruction during the follow-up period refused to participate in this report or to submit pictures.

4. Discussion

Women who carry a BRCA1/2 germ line mutation face a high lifetime risk for the development of breast and ovarian cancer [11–13]. Thus, the overall lifetime risk of breast cancer for women carrying a BRCA1/2 mutation is between 50% and 80%, while the lifetime risk for ovarian cancer is 15% to 40% [14]. Patients harboring BRCA1/2-mutated breast cancer tend to have an earlier age at onset—usually before 50 years of age, particularly for BRCA1 cancers, and a higher risk for contralateral breast cancer [4,15]. Consequently, bilateral salpingo-oophorectomy (BSO) and risk-reducing mastectomy (RRM) are often advocated for these women. While RRM markedly decreases the occurrence of breast cancer in BRCA mutation carriers, its effect on survival is less apparent [16], especially in patients who already developed breast cancer and face the hazard of systemic recurrence [17]. Notably, many BRCA carriers pursue alternative preventive measures because of fears related to detrimental effects of RRM on sensation, body image and sexuality [18]. Therefore, additional risk-reducing interventions are needed for carriers interested in breast conser-
vation. For BRCA carriers who already developed breast cancer, most studies found that the outcome of breast-conserving therapy (lumpectomy and whole breast radiotherapy) is comparable to non-carriers [19–21], but their risk of subsequent cancer in the contralateral breast is markedly increased [22,23]. Thus, it was recently reported that the 10-year cumulative risk of a second contralateral breast cancer was 23.9% in carriers diagnosed before age 41 and 12.6% in carriers who were first diagnosed at 41 to 49 years [22]. Given the propensity of Ashkenazi Jewish women to harbor BRCA mutations [2], the state of Israel has an enriched population with a unique risk profile. Accordingly, a national effort was launched in that country which engaged the majority of the Israeli oncologic community to plan and implement a trial to deal with the clinical, emotional and ethical ramifications of this disease. In our phase II nonrandomized trial, we found that prophylactic irradiation to the contralateral (ostensibly healthy) breast in BRCA carriers undergoing breast conserving treatment significantly reduced subsequent contralateral breast cancer [5]. Given the finite risk of failure, concern has been raised about the outcome of salvage and reconstructive procedures in the event that subsequent ipsilateral or contralateral cancer develop, as it has been suggested that antecedent breast irradiation may increase complications and jeopardize cosmesis of subsequent breast reconstruction [8]. Herein, we report 11 participants on the trial that had bilateral mastectomy and reconstruction within the follow-up period, including 14 breast reconstructions following breast irradiation and seven reconstructions of non-irradiated breasts. These results suggest that in this patient population of BRCA mutation carriers, previous breast irradiation does not compromise subsequent mastectomy and breast reconstruction. Admittedly, the numbers are small, and the assessment of reconstruction outcome was subjective and reflects the patients’ own experience and judgment of the treating physicians, mostly based on photos. However, the results are encouraging and may reassure high-risk patients who wish to preserve their breasts and choose prophylactic breast irradiation as a risk-reducing modality. Finally, the inclusion of actual photos gives BRCA carriers and the medical community the opportunity to directly examine the results of salvage RRM plus reconstruction and should promote the discussion of alternative primary risk-reducing options.

Genomic insights have provided opportunities to tailor therapies to specific populations. Although the majority of prospective trials in the era of precision medicine have been oriented around systemic therapies [24], radiation strategies should also be incorporated into such meticulous approaches to oncologic management. Indeed, while the genomic revolution has affected the delivery of immunotherapy, biological agents and chemotherapies, it has yet to be integrated into radiation-related strategies. A fundamental tenet of precision medicine is that therapies for cancer should be calibrated with tumor biology [24,25]. Although several recurrence risk signatures are summoned to guide the management of patients with node-negative breast cancer, only recently has preliminary validation of radiosensitivity molecular signatures emerged in the setting of breast cancer [26]. The use of prophylactic irradiation is admittedly controversial but seems to offer an effective alternative to healthcare providers as well as patients struggling with the clinical reality of BRCA mutations. Scrupulous reporting of outcomes must continue to be a manifestation of the moral commitment that investigators make to both of these stakeholders as radiation strategies become informed by biological principles.

Finally, we wish to emphasize that the integration of prophylactic irradiation in the management of the uninvolved breast in the setting of BRCA mutation carriers diagnosed with early-stage breast cancer constitutes a source of hope for women beset by the fears associated with this condition. Prophylactic irradiation of the breast is unencumbered by the significant implications for sexuality and body image that are associated with risk-reducing mastectomy. In this context, we do not refer to hope as an innate characteristic, but rather as a cognitive construct that can assist patients through the trajectory of illness [27]. A recent report has demonstrated that patients with breast cancer, as well as the oncologists who care for them, can be taught to enhance such hopefulness [28]. The advent of creative, non-invasive options in the management of a genomically defined subset of breast
cancer constitutes a welcome source of optimism for the concentric circles of patients and caregivers, as well as medical professionals.

5. Conclusions

Our findings are encouraging and support continuing research and discussion of risk-reduction alternatives, including prophylactic breast irradiation, in BRCA1/2 mutation carriers.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13112694/s1, Figure S1: Flow Chart.

Author Contributions: Conceptualization: M.A.B.D., E.E., B.W.C., Investigation: M.A.B.D., E.E., A.F.R., A.S. and B.W.C., writing—original draft preparation: E.E., B.W.C., M.A.B.D., A.F.R., A.S., writing—review and editing: E.E., B.W.C., M.A.B.D. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Israeli Cancer Association Grant No. C-20190082.

Institutional Review Board Statement: Permission to proceed with the aforementioned analysis was obtained from the Institutional Review Board (IRB) at Kaplan Medical Center (Rehovot, Israel). No. 0034-19-KMC.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The data presented in this study are available in this article (and supplementary material).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Levy-Lahad, E.; Friedman, E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 2007, 96, 11–15. [CrossRef]
2. Warner, E.; Foulkes, W.; Goodwin, P.; Meschino, W.; Blondal, J.; Paterson, C.; Ozcelik, H.; Goss, P.; Allingham-Hawkins, D.; Hamel, N.; et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J. Natl. Cancer Inst. 1999, 91, 1241–1247. [CrossRef]
3. Lakhan, S.R.; Jacquemier, J.; Sloane, J.P.; Gusterson, B.A.; Anderson, T.J.; van de Vijver, M.J.; Farid, L.M.; Venter, D.; Antoniou, A.; Storfer-Isser, A.; et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 1998, 90, 1138–1145. [CrossRef] [PubMed]
4. Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.A.; Mooij, T.M.; Roos-Blom, M.J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017, 317, 2402–2416. [CrossRef] [PubMed]
5. Evron, E.; Ben-David, A.M.; Goldberg, H.; Fried, G.; Kaufman, B.; Catane, R.; Pfeffer, M.R.; Geffen, D.B.; Chernobelsky, P.; Karni, T.; et al. Prophylactic irradiation to the contralateral breast for BRCA mutation carriers with early-stage breast cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019, 30, 412–417. [CrossRef]
6. Poortmans, P.M.P.; Kaidar-Person, O. Contralateral breast irradiation in BRCA carriers: The conundrum of prophylactic versus early treatment. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2019, 30, 348–350. [CrossRef]
7. Narod, S.A. Is bilateral radiation an option for BRCA mutation carriers with unilateral breast cancer? Ann. Transl. Med. 2019, 7, 165. [CrossRef] [PubMed]
8. Ho, A.Y.; Hu, Z.I.; Mehrara, B.J.; Wilkins, E.G. Radiotherapy in the setting of breast reconstruction: Types, techniques, and timing. Lancet Oncol. 2017, 18, e742–e753. [CrossRef]
9. Kaidar-Person, O.; Offersten, B.V.; Boersma, L.J.; de Ruyscher, D.; Tramm, T.; Kühn, T.; Gentilini, O.; Mátrai, Z.; Poortmans, P. A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges. Breast (Edinb. Scotl.) 2021, 56, 42–52. [CrossRef]
10. Spear, S.L.; Baker, J.L., Jr. Classification of capsular contracture after prosthetic breast reconstruction. Plast Reconstr. Surg. 1995, 96, 1119–1123, discussion 1124. [CrossRef]
11. Rebbeck, T.R.; Friebel, T.; Lynch, H.T.; Neuhausen, S.L.; van ’t Veer, L.; Garber, J.E.; Evans, G.R.; Narod, S.A.; Isaacs, C.; Matloff, E.; et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2004, 22, 1055–1062. [CrossRef]
12. Hartmann, L.C.; Sellers, T.A.; Schaid, D.J.; Frank, T.S.; Soderberg, C.L.; Sitta, D.L.; Frost, M.H.; Grant, C.S.; Donohue, J.H.; Woods, J.E.; et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J. Natl. Cancer Inst. 2001, 93, 1633–1637. [CrossRef]
13. Meijers-Heijboer, H.; van Geel, B.; van Putten, W.L.; Henzen-Logmans, S.C.; Seynaeve, C.; Menke-Pluymers, M.B.; Bartels, C.C.; Verhoog, L.C.; van den Ouweland, A.M.; Niermeijer, M.F.; et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. *N. Engl. J. Med.* 2001, 345, 159–164. [CrossRef]  
[PubMed]

14. Brose, M.S.; Rebbeck, T.R.; Calzone, K.A.; Stopfer, J.E.; Nathanson, K.L.; Weber, B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. *J. Natl. Cancer Inst.* 2002, 94, 1365–1372. [CrossRef]  
[PubMed]

15. Pierce, L.J.; Haffty, B.G. Radiotherapy in the treatment of hereditary breast cancer. *Semin. Radiat. Oncol.* 2011, 21, 43–50. [CrossRef]  
[PubMed]

16. Heemskerk-Gerritsen, B.A.M.; Jager, A.; Koppert, L.B.; Obdeijn, A.I.; Collée, M.; Meijers-Heijboer, H.E.J.; Jenner, D.J.; Oldenburg, H.S.A.; van Engelen, K.; de Vries, J.; et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. *Breast Cancer Res. Treat.* 2019, 177, 723–733. [CrossRef]  
[PubMed]

17. Tung, N.M.; Boughey, J.C.; Pierce, L.J.; Robson, M.E.; Bedrosian, I.; Dietz, J.R.; Dragun, A.; Gelpi, J.B.; Hofstatter, E.W.; Isaacs, C.J.; et al. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2020, 38, 2080–2106. [CrossRef]  
[PubMed]

18. Metcalfe, K.; Eisen, A.; Senter, L.; Armel, S.; Bordeleau, L.; Meschino, W.S.; Pal, T.; Lynch, H.T.; Tung, N.M.; Kwong, A.; et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. *Br. J. Cancer* 2019, 121, 15–21. [CrossRef]  
[PubMed]

19. Pierce, L.J.; Levin, A.M.; Rebbeck, T.R.; Ben-David, M.A.; Friedman, E.; Solin, L.J.; Harris, E.E.; Gaffney, D.K.; Haffty, B.G.; Dawson, L.A.; et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2006, 24, 2437–2443. [CrossRef]  
[PubMed]

20. Pierce, L.J.; Strawderman, M.; Narod, S.A.; Oliviotto, I.; Eisen, A.; Dawson, L.; Gaffney, D.; Solin, L.J.; Nixon, A.; Garber, J.; et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2000, 18, 3360–3369. [CrossRef]  
[PubMed]

21. Van den Broek, A.J.; Schmidt, M.K.; van ’t Veer, L.J.; Oldenburg, H.S.A.; Rutgers, E.J.; Russell, N.S.; Smit, V.; Voogd, A.C.; Koppert, L.B.; Siesling, S.; et al. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. *Ann. Surg.* 2019, 270, 364–372. [CrossRef]  
[PubMed]

22. Van den Broek, A.J.; van ’t Veer, L.J.; Hooning, M.J.; Cornelissen, S.; Broeks, A.; Rutgers, E.J.; Smit, V.T.; Cornelisse, C.J.; van Beek, M.; Janssen-Heijnen, M.L.; et al. Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 2016, 34, 409–418. [CrossRef]  
[PubMed]

23. Robson, M.; Gilewski, T.; Haas, B.; Levin, D.; Borgen, P.; Rajan, P.; Hirschaut, Y.; Pressman, P.; Rosen, P.P.; Lesser, M.L.; et al. BRCA-associated breast cancer in young women. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* 1998, 16, 1642–1649. [CrossRef]  
[PubMed]

24. Sparano, J.A.; Gray, R.J.; Ravdin, P.M.; Makower, D.F.; Pritchard, K.I.; Albain, K.S.; Hayes, D.F.; Geyer, C.E., Jr.; Dees, E.C.; Goetz, M.P.; et al. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. *N. Engl. J. Med.* 2019, 380, 2395–2405. [CrossRef]  
[PubMed]

25. Scott, J.G.; Berglund, A.; Schell, M.J.; Mihaylov, I.; Fulp, W.J.; Yue, B.; Welsh, E.; Caudell, J.J.; Ahmed, K.; Strom, T.S.; et al. A genome-based model for adjusting radiotherapy dose (GARD): A retrospective, cohort-based study. *Lancet Oncol.* 2017, 18, 202–211. [CrossRef]  
[PubMed]

26. Eschrich, S.A.; Fulp, W.J.; Pavitan, Y.; Foekens, J.A.; Smid, M.; Martens, J.W.; Echevarria, M.; Kamath, V.; Lee, J.H.; Harris, E.E.; et al. Validation of a radiosensitivity molecular signature in breast cancer. *Clin. Cancer Res.* 2012, 18, 5134–5143. [CrossRef]  
[PubMed]

27. Corn, B.W.; Feldman, D.B.; Wexler, I. The science of hope. *Lancet Oncol.* 2020, 21, e452–e459. [CrossRef]  
[PubMed]

28. Shah, M.; Ferguson, A.; Corn, P.D.; Varadhan, R.; Ariely, D.; Stearns, V.; Smith, B.D.; Smith, T.J.; Corn, B.W. Developing Workshops to Enhance Hope Among Patients With Metastatic Breast Cancer and Oncologists: A Pilot Study. *JCO Oncol. Pract.* 2021, Op2000744. [CrossRef]